Stock Ratings / Health Care / ADPT / financials

IOVA (48) CRSP (44) SRRK (42) CGON (42) ⌘ Pro Terminal →

Adaptive Biotechnologies Corporation (ADPT) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$28.17 -0.70% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Adaptive Biotechnologies Corporation (ADPT) carries a Roarable Rating of D (Sell) with 51/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $4.50B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-3.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ADPT)Realized 20D OHLCV Swing Band: ±12.4%

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How ADPT Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $170.3M

FY24

Rev $179.0M

FY25

Rev $277.0M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$277.0M	74.2%	-20.6%	-$59.5M	-$48.9M	-16.4%
FY 2024	$179.0M	59.7%	-90.8%	-$159.5M	-$98.9M	-44.7%
FY 2023	$170.3M	74.2%	-133.3%	-$225.3M	-$164.0M	-12%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ADPT)

✓Walkthrough of ADPT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ADPT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +94.28%▲ ASCENDING CHANNEL

2026-11-01O $28.37H $28.37L $28.17C $28.17VOL 2.59M

RES: $32.92SUP: $24.14SMA50: $26.42SMA200: $19.66

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ADPT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ADPT Butterfly Map → + Track ADPT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

19.7%/yr Implied 5Y Growth

vs. +54.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ADPT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ADPT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ADPT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ADPT)

Health Care Rank #150 of 188 ⚔️ IOVA vs ADPT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ADPT vs. IOVA, CRSP, SRRK, CGON)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (26 Tracked Issuers)

Across 188 tracked Health Care securities in the Roarable RQD universe, Adaptive Biotechnologies Corporation (ADPT) ranks #150 by composite RQD confidence (51/100, grade D) and #164 by equity capitalization ($4.50B). Within this direct 5-issuer industry benchmark cohort, ADPT leads on earnings valuation at N/A trailing P/E, while ADPT leads on capital efficiency and profitability with -12.5% ROIC and 74.2% gross margin. ADPT currently leads its immediate peer cohort in composite quantitative strength at 51/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ADPT ACTIVE Adaptive Biotechnologies Corporation	D	51/100	—	74.2%	-12.5%	-0.70%	$4.50B	Benchmark Subject
IOVA Iovance Biotherapeutics Inc.	D	48/100	—	34.3%	-35.0%	-35.45%	$4.33B	/iova-vs-adpt →
CRSP CRISPR Therapeutics AG	D	44/100	—	—	-30.6%	+0.28%	$5.25B	/crsp-vs-adpt →
SRRK Scholar Rock Holding Corporation	D-	42/100	—	—	-35.0%	+2.15%	$5.38B	/srrk-vs-adpt →
CGON CG Oncology Inc.	D-	42/100	—	—	-20.8%	-0.77%	$5.63B	/cgon-vs-adpt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001478320

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Adaptive Biotechnologies Corporation (ADPT) reported GAAP revenue of $277.0M (+54.8% vs. FY2024 revenue of $179.0M , and +62.7% cumulative change since FY2023) , GAAP net income of -$59.5M, operating cash flow of -$46.0M, and free cash flow of -$48.9M (+50.5% YoY). On the balance sheet, ADPT closed FY2025 with $512.7M in total assets against $126.6M in total debt (Altman Z-Score: 6.32, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$277.0M	-$59.5M	-$46.0M	-$48.9M	$512.7M	$126.6M
FY2024 (FY)	2024-12-31	$179.0M	-$159.5M	-$95.2M	-$98.9M	$539.4M	$132.4M
FY2023 (FY)	2023-12-31	$170.3M	-$225.3M	-$156.3M	-$164.0M	$2.47B	$578.6M

3. ADPT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ADPT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Adaptive Biotechnologies Corporation (NASDAQ: ADPT) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $28.17 (-0.70% 1D, market cap $4.50B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 17/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 188 tracked Health Care issuers, ADPT ranks #150 in composite RQD confidence.

How does ADPT compare to IOVA and CRSP in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ADPT carries a Roarable D (51/100 RQD), trailing P/E of N/A, gross margin of 74.2%, and ROIC of -12.5%. By comparison, IOVA (Iovance Biotherapeutics Inc.) holds a D grade (48/100 RQD, P/E N/A, ROIC -35.0%, cap $4.33B) and CRSP (CRISPR Therapeutics AG) posts a D grade (44/100 RQD, P/E N/A, ROIC -30.6%, cap $5.25B). Among the 5-stock peer group, ADPT leads on earnings multiple (N/A) while ADPT leads on capital efficiency (-12.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ADPT?

Per ADPT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001478320), Adaptive Biotechnologies Corporation generated $277.0M in revenue (+54.8% YoY), -$59.5M in net income, and -$48.9M in free cash flow against $512.7M in total assets and $126.6M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ADPT trading relative to its 50-day, 200-day, and 52-week technical levels?

ADPT last traded at $28.17 (-0.70% on volume of 2,588,942 shares), positioning the stock +6.62% above its 50-day simple moving average ($26.42) and +43.29% above its 200-day simple moving average ($19.66). Across its 52-week range of $12.00 to $30.74, ADPT sits at the 86.3% percentile with a 14-day RSI of 57.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.4% ($24.68 to $31.66).

ADPT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Adaptive Biotechnologies Corporation (ADPT)?

In FY 2025 (10-K), ADPT converted $277.0M of revenue into a 74.2% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: ADPT RQD Cockpit ADPT 12M Forecast ADPT Earnings & Move ADPT Dividends & DRIP ADPT Insiders & 13F ADPT Whale Options ADPT Profit Sankey ADPT News & Why